Jefferies initiated coverage of Procept BioRobotics (PRCT) with a Hold rating and $95 price target The firm’s checks suggest the Hydros system launch could catalyze a replacement cycle among systems more than two years old and drive more surgeon adoption, but it sees a more limited ambulatory surgical center, or ASC, opportunity and thinks the current valuation limits the stock price upside.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRCT:
- PROCEPT BioRobotics (PRCT) Continues to Invest in Labor-Saving Robotics
- Procept BioRobotics price target raised to $105 from $95 at Truist
- Procept BioRobotics 1.92M share Spot Secondary priced at $91.00
- Procept BioRobotics announces $175M common stock offering
- Boeing to offer 90M common shares, Philips reports mixed Q3: Morning Buzz